Impact Post-operative Treatment on Intraocular Pressure Post-SLT on Patients With Primary Open-angle Glaucoma (SLT)
Impact of the Post-operative Treatment on the Intraocular Pressure Post Selective Laser Trabeculoplasty (SLT) on Patients With Primary Open-angle Glaucoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Québec, Quebec, Canada, G1S 4L8
- Centre universitaire d'ophtalmologie, Hôpital du Saint-Sacrement, CHU de Québec
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients suffering from with primary open-angle glaucoma.
- Patients with IOP > 21 mmHg, uncontrolled with medical treatment or due to non-compliance, or to whom this is the first glaucoma treatment.
- Patients > 18 years old, able to consent.
- Patients consenting to the trial.
Exclusion Criteria:
- Patients suffering from chronic glaucoma other than primary open-angle glaucoma
- Patients who had changes done to their anti-glaucoma treatments over the last 6 weeks or following the SLT
- Patients under oral corticosteroid treatment at the time of the operation or those who have stopped during the preceding month.
- Patients suffering from an important corneal disease which interferes with the capacity to visualize the entire trabeculae.
- Monophthalmic patients.
- Patients who already underwent a glaucoma treatment to the eye requiring treatment.
- Patients who already underwent a glaucoma treatment using SLT or ALT (Argon laser trabeculoplasty)
- Patients who underwent cataract surgery in the past 3 months.
- Pregnant patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Prednisone acetate 1%
A topic cortisone-based treatment
|
The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye.
Fifty spots are done over 180°.
The maximal and total energy is written in the chart.
After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used.
The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
|
|
Active Comparator: diclofenac 0.1%
an non-steroidal anti-inflammatory drug
|
The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye.
Fifty spots are done over 180°.
The maximal and total energy is written in the chart.
After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used.
The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
|
|
Placebo Comparator: Artificial Tears
Pharmasciences DIN: 02229570
|
The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye.
Fifty spots are done over 180°.
The maximal and total energy is written in the chart.
After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used.
The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intraocular pressure in the treated eye
Time Frame: 1 hour, 7 days, 1.5, 3 and 6 months
|
1 hour, 7 days, 1.5, 3 and 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Side effects (include a slight uveitis, oculary discomfort and a spike in intraocular pressure in the immediate post-op period)
Time Frame: 1 hour, 7 days, 1.5 months, 3 months and 6 months
|
1 hour, 7 days, 1.5 months, 3 months and 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Béatrice Des Marchais, FRCSC M.Sc., CHU de Quebec-Universite Laval
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DR-002-1213
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.